舒洛地特联合坎地沙坦治疗糖尿病肾病4期患者临床疗效观察

目的 观察舒洛地特联合坎地沙坦治疗糖尿病肾病4期的临床疗效. 方法 选取厦门大学附属成功医院于2014年8月至2015年10月间收治的48例糖尿病肾病4期患者作为研究对象,并将其随机分为舒洛地特组(14例)、坎地沙坦组(17例)及联合治疗组(17例),所有患者均随访12周,比较各组患者的临床有效率、24h尿蛋白、血浆白蛋白(ALB)、血肌酐(SCr)、总胆固醇(CHOL)、纤维蛋白原(FIB). 结果 治疗后3组患者尿蛋白水平较治疗前明显改善(P<0.05),舒洛地特组尿蛋白量下降水平与坎地沙坦组比较差异无统计学意义(P>0.05),联合治疗组尿蛋白量下降水平优于单独用药两组(P<0.05),舒洛地特及联合治疗组治疗后FIB有显著下降(P<0.05).各组患者ALB、SCr、CHOL在治疗前后比较差异无统计学意义(P>0.05). 结论 舒洛地特联合坎地沙坦能有效减少糖尿病肾病4期患者的尿蛋白水平,效果优于单一用药.

Efficacy observation of sulodexide and candesartan on 48 cases with diabetic nephropathyIV stage

Objective To explore the clinical effect of sulodexide and candesartan on patients with diabetic nephropathy IV stage.Methods 48 patients with DN-IV stage were randomized divided into sulodexide group (14 cases), candesartan group (17 cases), candesartan and sulodexide group(17 cases) from 2014 August to 2015 October in the Cheng-gong Affiliated Hospital of Xiamen University.The follow-up was 12 weeks.After the treatment, the clinical efficiency, 24 h urinary protein, plasma albumin(ALB),serum creatinine (SCr), total cholesterol(CHOL), fibrinogen(FIB) were compared in three groups.Results Compared with those before treatment, the urinary protein of the three groups after treatment was significantly lower (P<0.05);while the 24 h urinary protein of sulodexide group and candesartan group was not significant different (P>0.05), and the urinary protein of the candesartan and sulodexide group were better than the other two groups (P<0.05);After the treatment the FIB of sulodexide group and candesartan and sulodexide group was significantly decreased (P<0.05);while there was no significant difference in ALB, SCr and CHOL of those groups before and after treatment (P> 0.05).Conclusion Sulodexide and candesartan get a satisfactory result on reducing the urinary protein level in the treatment of diabetic nephropathy IV stage.